Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models

Oncotarget

Volumn 7, Issue 50, 2016, Pages 82482-82492

  Wolfe, Adam R ^a   Trenton, Nicholaus J ^b   Debeb, Bisrat G ^a   Larson, Richard ^a   Ruffell, Brian ^c   Chu, Khoi ^a   Hittelman, Walter ^a   Diehl, Michael ^b   Reuben, Jim M ^a   Ueno, Naoto T ^a   Woodward, Wendy A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Rice University   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

IL 6; Inflammatory breast cancer; Macrophages; Mesenchymal stem cells; Statins

Indexed keywords

COLONY STIMULATING FACTOR 1 ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; PROTEIN ANTIBODY; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; IL6 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CANCER RECURRENCE; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL POLARITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BREAST CANCER; MACROPHAGE; MAMMARY GLAND FAT; MDA IBC3 CELL LINE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PHENOTYPE; RAW 264.7 CELL LINE; SUM 149 CELL LINE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; MESENCHYMAL STROMA CELL; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR RECURRENCE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MESENCHYMAL STROMAL CELLS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PARACRINE COMMUNICATION; PHOSPHORYLATION; RAW 264.7 CELLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 85003936053     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12694     Document Type: Article

References (25)

1. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, H. Le-Petross, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010; 60:351-75.
2. Atkinson R, Yang W, Rosen D, Landis M, Wong H, Lewis M, Creighton C, Sexton K, Hilsenbeck S, Sahin A, Brewster A, Woodward W, Chang J. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research. 2013; 15:R77.
3. Baumgarten SC, Frasor J. Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol. 2012; 26:360-71.
4. Hussein, M.R. and Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006; 59:972-7.
5. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 2007; 67:11687-95.
6. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011; 71:614-24.
7. Adutler-Lieber S, T. Ben-Mordechai, N. Naftali-Shani, Asher E, Loberman D, Raanani E, Leor J. Human Macrophage Regulation Via Interaction With Cardiac Adipose Tissue-Derived Mesenchymal Stromal Cells. J Cardiovasc Pharmacol Ther. 2012.
8. Fujita E, Soyama A, Momoi T. RA175, which is the mouse ortholog of TSLC1, a tumor suppressor gene in human lung cancer, is a cell adhesion molecule. Experimental Cell Research. 2003; 287:57-66.
9. Loppnow H, Zhang L, Buerke M, Lautenschläger M, Chen L, Frister A, Schlitt A, Luther T, Song N, Hofmann B, Rose-John S, Silber RE, Müller-Werdan U, et al. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. Journal of Cellular and Molecular Medicine. 2011; 15:994-1004.
10. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010; 115:1461-71.
11. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16:91-102.
12. Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, Krishnamurthy S, Gong Y, Levy LB, Buchholz T, Ueno NT, Klopp A, Woodward WA. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res. 2015; 17:42.
13. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer. 2005; 41:2502-2512.
14. Gordon S. The macrophage: past, present and future. Eur J Immunol. 2007; 37:S9-17.
15. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009; 9:259-70.
16. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. 2005; 175:342-9.
17. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009; 27:451-83.
18. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003; 73:209-12.
19. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007; 104:11002-7.
20. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009; 15:42-9.
21. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22:1517-27.
22. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139:1315-26.
23. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008; 118:3367-77.
24. Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, and Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013; 15:R79.
25. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1:54-67.